Alexza Pharmaceuticals Inc

Alexza Pharmaceuticals — Non-Deal Roadshow (May 2008)

28 slides from Alexza Pharmaceuticals's roadshow presentation, May 16, 2008

  1. Slide 1: Investor Roadshow - May 2008

    Investor Roadshow - May 2008

  2. Slide 2: Forward-looking statements

    Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the initiation and completion of clinical trials, the potential advantages of Alexza's product candidates and the Company's capital

  3. Slide 3: The Alexza Opportunity

    The Alexza Opportunity Strong pipeline - six Staccato product candidates first Phase 3 trial (AZ-004) initiated Q1 08 6th product candidate (AZ-007) Phase 1 initiated/enrolled Q1 08 two partnerships - Endo Pharmaceuticals and Symphony Allegro Revolutionary treatments for acute & intermittent conditi

  4. Slide 4: Staccato Technology

    Staccato Technology Single-Dose Device, Used in 5 of 6 Product Candidates mouthpiece heat package battery to initiate heating airflow drug coating 0.5 sec

  5. Slide 5: The Staccato Advantage: Demonstrated IV-like Pharmacokinetics

    The Staccato Advantage Demonstrated IV-like Pharmacokinetics Different compounds exhibit similar time to Cmax Dog studies (drug levels measured in left ventricle) Phase 1 studies in healthy volunteers (venous blood drug levels)

  6. Slide 6: The Staccato Advantage Summary Characteristics

    The Staccato Advantage Summary Characteristics Rapid, reproducible IV-like pharmacokinetics Proprietary technology: ^ 97% purity ideal aerosol particle size MMAD in the 1 - 3 µm range No excipients or additives / no formulation water soluble and insoluble compounds Reliable and consistently high emi

  7. Slide 7: We Are NOT "Inhaled Insulin"

    The Staccato Advantage We Are NOT "Inhaled Insulin" Inhaled Dry Powder Insulin Staccato Aerosols API protein hormone (growth factor) small molecule Formulation multiple dry powder excipients excipient-free aerosol Administration Frequency multiple inhalations 3 - 4 times each day single inhalation 1

  8. Slide 8: The Alexza Clinical Pipeline - Then (Summer 2004)

    The Alexza Clinical Pipeline - Then Summer 2004 - Series D Financing End of P2 Meeting Phase 2b Phase 2a Phase 1 IND AZ-001 Migraine (Staccato prochlorperazine) Phase 3 AZ-003 BTP (Staccato fentanyl) AZ-004 Acute Agitation (Staccato loxapine) AZ-002 Panic Attack (Staccato alprazolam)

  9. Slide 9: The Alexza Clinical Pipeline - Then (December 2006)

    The Alexza Clinical Pipeline - Then December 2006 - Post-IPO End of P2 Meeting Phase 2b Phase 2a Phase 1 IND AZ-001 Migraine (Staccato prochlorperazine) Phase 3 AZ-003 BTP (Staccato fentanyl) AZ-004 Acute Agitation (Staccato loxapine) AZ-002 Panic Attack (Staccato alprazolam)

  10. Slide 10: The Alexza Clinical Pipeline - Now (May 2008)

    The Alexza Clinical Pipeline - Now Today - May 2008 End of P2 Meeting Phase 2b Phase 2a Phase 1 IND AZ-001 Migraine (Staccato prochlorperazine) AZ-002 Panic Attack (Staccato alprazolam) Phase 3 AZ-104 Migraine (Staccato loxapine) AZ-003 BTP (Staccato fentanyl) AZ-004 Acute Agitation (Staccato loxapi

  11. Slide 11: AZ-004 for Acute Agitation: Product Rationale

    AZ-004 for Acute Agitation Product Rationale for Staccato Loxapine US target population is 7.9 million patients 2.2 million schizophrenia patients, 5.7 million bipolar disorder patients Agitation is one of the most common symptoms approximately 50% can require an admission 69% of those with agitatio

  12. Slide 12: AZ-004 Phase 2 Clinical Trial Results

    AZ-004 Phase 2 Clinical Trial Results 10 mg Dose Met the Primary Endpoint PANSS Excited Component (PEC) Assessment Reduction in Agitation (at 2 hours) N=43 N=45 N=41 p=0.0001 p=0.088

  13. Slide 13: PANSS Excited Component Assessment Total Score

    PANSS Excited Component (PEC) Assessment Total Score N=43 N=45 N=41 Mean + SEM AZ-004 Phase 2 Clinical Trial Results Clinically Significant Results - 50% Reduction in Agitation

  14. Slide 14: Rapid Onset and Sustained Reduction of Agitation

    AZ-004 Phase 2 Clinical Trial Results Rapid Onset and Sustained Reduction of Agitation p-value at time point p-value at time point p-value at time point p-value at time point p-value at time point p-value at time point p-value at time point p-value at time point p-value at time point 10 min 20 min 3

  15. Slide 15: Generally Safe and Well-Tolerated, No SAEs

    AZ-004 Phase 2 Clinical Trial Results Generally Safe and Well-Tolerated, No SAE's Placebo 5 mg 10 mg Any AE, N (%) 16 (37%) 15 (33%) 18 (44%) Dysgeusia, N (%) 4 (9%) 2 (4%) 7 (17%) Dizziness, N (%) (mild only) 4 (9%) 5 (11%) 2 (5%) Sedation, N (%) (moderate) 6 (14%) 1 (2%) 6 (13%) 2 (4%) 9 (22%) 4 (

  16. Slide 16: AZ-004 for Acute Agitation: Clear NDA Pathway Established

    AZ-004 for Acute Agitation Clear NDA Pathway Established Completed Phase 1 & 2, including a multi-dose PK study (> 200 subjects / patients) End of Phase 2 meeting with FDA validated clinical endpoints (3 approved products for acute agitation) NDA Plan - two Phase 3 clinical trials initiated first Ph

  17. Slide 17: Alexza Psychiatry Focus: Specialty Sales Force Targeting

    Office-based MDs Psychiatry MDs N = 50,000 Alexza Psychiatry Focus Specialty Sales Force Targeting Hospital or Clinic-based MDs N = 6,000 ED Psych ED In-Patient Facilities Initial AZ-004 MD Target

  18. Slide 18: Acute Agitation Market Marketplace Topography

    Admit or Discharge Community Emergency Department Psychiatric Emergency Department Inpatient Facility agitation episode Discharge 5 - 20 days multiple agitation episodes Easton Associates, March 2008 Acute Agitation Market Marketplace Topography

  19. Slide 19: Frequency of Agitation Episodes per Year

    1-3 4-6 7-9 10-15 16+ 49 20 12 13 6 Frequency of Agitation Episodes per Year (schizophrenia and bipolar patients) Weighted Average = 5.8 Agitation Episodes per Year Frequency of Agitation Episodes per Year

  20. Slide 20: Types of Acute Agitation and Treatments

    Types of Acute Agitation Types of Treatments Low Agitation 36% Moderate Agitation 37% High Agitation 27% No Rx 11% ODT 18% IM Injection 36% Oral Tablets 35%

  21. Slide 21: AZ-004 Initial Market Opportunity

    Oral Meds Mild Agitation Moderate Agitation High Agitation IM Injection Meds AZ-004 Initial Opportunity AZ-004 Initial Market Opportunity In-Clinic Acute Agitation Market

  22. Slide 22: The Alexza Clinical Pipeline May 2008

    The Alexza Clinical Pipeline May 2008 End of P2 Meeting Phase 2b Phase 2a Phase 1 IND AZ-001 Migraine (Staccato prochlorperazine) AZ-002 Panic Attack (Staccato alprazolam) Phase 3 AZ-003 BTP (Staccato fentanyl) AZ-104 Migraine (Staccato loxapine) AZ-004 Acute Agitation (Staccato loxapine) AZ-007 Sle

  23. Slide 23: 2008 Accomplishments and Milestones

    The Alexza Clinical Pipeline 2008 Accomplishments and Milestones Product Candidates 2008 Accomplishments 2008 Milestones AZ-004 (Staccato loxapine) ^ first Phase 3 start ^ APA presentation • second Phase 3 start AZ-002 (Staccato alprazolam) ^ Phase 2a enrollment • Phase 2a initial data • Phase 2b tr

  24. Slide 24: An IP Portfolio Both Broad ...

    An IP Portfolio Both Broad ... Manufacture of device Specific features of device Method of producing aerosol Method of administering to a patient Device for producing aerosol Kit comprising device Aerosol composition of matter Method of treating a disease

  25. Slide 25: ... and Increasingly Deep

    2003 2004 2005 2006 2007 Current US Patents 15 23 46 70 68 73 Non-US Patents 1 20 41 Pending US Applications 45 71 52 48 55 51 Pending non-US Nationals & PCT Applications 87 96 139 144 142 120 .... and Increasingly Deep > 110 Issued and Allowed Patents

  26. Slide 26: Summary Financials - Q1 2008

    Summary Financials - Q1 2008 Cash - $111.7 million (as of March 31, 2008) cash, equivalents, marketable securities - $75.7 million investment held by Symphony Allegro - $35.9 million Additional transactions - Q1 08 Endo partnership for AZ-003 - $10 million upfront payment Bio*One Capital - $10 milli

  27. Slide 27: Key 2008 Milestones

    2H 2008 initiate second AZ-004 P3 study conduct AZ-001 end of P2 meeting complete Singapore mfg JV identify development plans for AZ-104, AZ-002 and AZ-007 presentations (Migraine Trust - UK) 1H 2009 initial AZ-004 P3 results initiate AZ-004 supporting studies Key 2008 Milestones 1H 2008 initiate fi

  28. Slide 28: Alexza Pharmaceuticals

    ALEXZA PHARMACEUTICALS

Alexza Pharmaceuticals — Non-Deal Roadshow (May 2008) on 6ix